Avidity biosciences announces positive topline del-zota data demonstrating consistent, statistically significant improvements in dystrophin, exon skipping and creatine kinase in people living with duchenne muscular dystrophy amenable to exon 44 skipping in phase 1/2 explore44® trial

On track for year end 2025 bla submission for accelerated approval of 5 mg/kg every six weeks of del-zota in dmd44 consistent favorable safety and tolerability across del-zota dose cohorts  plan to present functional data in fourth quarter of 2025 investor and analyst webcast event today at 8:00 a.m. et san diego , march 17, 2025 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced positive del-zota topline data from the phase 1/2 explore44® trial in people living with duchenne muscular dystrophy amenable to exon 44 skipping (dmd44) demonstrating consistent, statistically significant improvements in dystrophin, exon skipping and creatine kinase as well as favorable safety and tolerability across the dose cohorts.
RNA Ratings Summary
RNA Quant Ranking